ArticleJournal of neurology, neurosurgery, and psychiatry1998
Susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus is associated with a polymorphism at the 5' end of the aldose reductase gene.
Article in Journal of neurology, neurosurgery, and psychiatry, 1998. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 82 citations in OpenAlex.
- Correlation between erythrocyte aldose reductase level and human diabetic retinopathy.The British journal of ophthalmology · 2002Trial
- Genetic Variants Influence the Development of Diabetic Neuropathy.International journal of molecular sciences · 2024Review
- AiScience · 2023Article
- Methylglyoxal and Its Adducts: Induction, Repair, and Association with Disease.Chemical research in toxicology · 2022Review
- Genetic and Epigenomic Modifiers of Diabetic Neuropathy.International journal of molecular sciences · 2021Review
- Aldose reductase (AC)n gene polymorphism in Iranian patients with type 2 diabetic microangiopathy; a case-control study.Diabetology international · 2021Article
- Aldose Reductase: An Emerging Target for Development of Interventions for Diabetic Cardiovascular Complications.Frontiers in endocrinology · 2021Review
- Identifying Common Genetic Risk Factors of Diabetic Neuropathies.Frontiers in endocrinology · 2015Review
- ALDOSE REDUCTASE: New Insights for an Old Enzyme.Biomolecular concepts · 2011Article
- VEGF gene polymorphism association with diabetic neuropathy.Molecular biology reports · 2010Article
- Aldose reductase and cardiovascular diseases, creating human-like diabetic complications in an experimental model.Circulation research · 2010Review
- Therapeutic strategies for diabetic neuropathy.Current neurology and neuroscience reports · 2010Review
- NFkappaB polymorphisms and susceptibility to type 1 diabetes.Genes and immunity · 2001Article
- Risk Factors and Comorbidities in Diabetic Neuropathy: An Update 2015.The review of diabetic studies : RDSReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThere is evidence that the polyol pathway is involved in the pathogenesis of diabetic neuropathy. Aldose reductase (ALR2) is the first and rate limiting enzyme of this pathway and recent studies have suggested that polymorphisms in and around the gene are associated with the development of diabetic microvascular disease. The aim was to examine the role of ALR2 in the susceptibility to diabetic neuropathy in patients with insulin dependent diabetes mellitus (IDDM).
methodsOne hundred and fifty nine British white patients with IDDM and 102 normal healthy controls were studied using the polymerase chain reaction to test for a highly polymorphic microsatellite marker 2.1 kilobase (kb) upstream of the initiation site of the ALR2 gene.
resultsSeven alleles were detected (Z-6, Z-4, Z-2, Z, Z+2, Z+4, and Z+6). There was a highly significant decrease in the frequency of the Z+2 allele in those patients with overt neuropathy compared with those with no neuropathy after 20 years duration of diabetes (14.1% v 38.2%, chi2 =17.3, p<0.00001). A similar difference was also found between the neuropathy group and those patients who have had diabetes for < five years with no overt neuropathy (14.1% v 30.2%, chi2=9.0, p<0.0025). The neuropathy group also had a significant decrease in the frequency of the Z/Z+2 genotype compared with those patients who have no neuropathy after 20 years duration of diabetes (14.0% v 44.7%, chi2=13.0, p<0.0005).
conclusionThese results suggest that the aldose reductase gene is intimately involved in the pathogenesis of diabetic neuropathy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.